GCM
AKBA icon

Graham Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Graham Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$345K Sell
248,352
-128,212
-34% -$176K 0.01% 764
2025
Q4 		$606K Buy
376,564
+146,588
+64% +$307K 0.01% 557
2025
Q3 		$628K Buy
229,976
+191,817
+503% +$638K 0.01% 534
2025
Q2 		$139K Buy
38,159
+20,606
+117% +$56.6K ﹤0.01% 1179
2025
Q1 		$33.7K Buy
+17,553
New +$35.8K ﹤0.01% 1241
2024
Q3 		– Sell
-57,624
Closed -$58.8K – 1077
2024
Q2 		$58.8K Buy
57,624
+28,838
+100% +$35.6K ﹤0.01% 981
2024
Q1 		$52.7K Buy
28,786
+5,153
+22% +$8.24K ﹤0.01% 1010
2023
Q4 		$29.3K Buy
+23,633
New +$24.1K ﹤0.01% 950
2023
Q3 		– Sell
-26,586
Closed -$24.3K – 994
2023
Q2 		$24.3K Buy
+26,586
New +$25.7K ﹤0.01% 929

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Graham Capital Management's AKBA Position: Q1 2026 in Review

Graham Capital Management reduced its Akebia Therapeutics (AKBA) stake by 34% in Q1 2026, selling an estimated $176K and leaving 248,352 shares worth $345K. The position accounts for 0.01% of the portfolio, ranked #764.

Graham Capital Management first reported a position in AKBA in Q2 2023 and has held it in 9 quarters since. The position peaked at $628K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Graham Capital Management held 248,352 shares of Akebia Therapeutics worth $345K as of Q1 2026.
  • Graham Capital Management sold 128,212 Akebia Therapeutics shares in Q1 2026, an estimated $176K.
  • Akebia Therapeutics made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #764 holding.
  • Graham Capital Management first reported a position in Akebia Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • Graham Capital Management's Akebia Therapeutics position peaked at $628K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.